Previous 10 | Next 10 |
The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with their 2018 Q3 earnings Read more ...
Amicus Therapeutics ( FOLD ) Q3 results: Revenues: $20.6M (+89.0%). More news on: Amicus Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
Amicus Therapeutics (NASDAQ: FOLD ): Q3 EPS of -$0.84 may not be comparable to consensus of -$0.28. More news on: Amicus Therapeutics, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
U.S. Galafold ® (Migalastat) Fabry Launch Tracking Significantly Ahead of Expectations- 100+ Patients Prescribed Galafold Since August Launch 3Q18 Global Galafold Net Product Sales of $20.6M Driven by Continued International Growth - 500+ International Fabry Patient...
CNA , CYOU , DEA , DO , DXPE , FOLD , HUD , INVH , KMPR , KOS , L , NS , OHI , PCG , PEGI , PGRE , RACE , RBC , SEAS , SHO , SOGO , SOHU , SRC , SYY , TA , WBT , WRK , XENT , XHR For Seeking Alpha's full earnings season calendar, click here . More ne...
Company overview Abeona Therapeutics (ABEO) is a clinical stage biopharmaceutical company focused on gene and cell therapy for rare genetic disease. This company has a long history starting from Access Pharmaceuticals established in 1974. It evolved with several mergers and acquisitions in...
Intellia Therapeutics (NASDAQ: NTLA ) initiated with Neutral rating and $24 (21% upside) price target at Credit Suisse. Shares up 1% premarket. More news on: Intellia Therapeutics, Inspire Medical Systems, Inc., Kodiak Sciences, Healthcare stocks news, Stocks on the move, , ...
NEW YORK, NY / ACCESSWIRE / October 29, 2018 / U.S. equities rolled back on Friday as disappointing corporate earnings added to the bearish sentiment in the market. The Dow Jones Industrial Average shed 1.19 percent to close at 24,688.31, while the S&P 500 Index decreased 1.73 percent t...
CRANBURY, N.J., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 5, 2018 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2018. ...
NEW YORK, Oct. 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of PennyMac Mortgage Investment Trust (NYSE:PMT), Amicus Therapeutics, In...
News, Short Squeeze, Breakout and More Instantly...
Amicus Therapeutics Inc. Company Name:
FOLD Stock Symbol:
NASDAQ Market:
Amicus Therapeutics Inc. Website:
2024-07-01 16:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45 th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 11, 2024, at 4:00 p.m. E.T. A live audio...
PRINCETON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the Galien Foundation has awarded the 2024 Prix Galien U.K....